Elizabeth Lihua Budde, MD, PhD, breaks down the design and baseline characteristics of the phase 3 POLARIX trial that led to the approval of polatuzumab in combination with R-CHP for certain patients with diffuse large B-cell lymphoma.
Elizabeth Lihua Budde, MD, PhD
Advertisement
Elizabeth Lihua Budde, MD, PhD, is a hematologist-oncologist at City of Hope.
Articles by Elizabeth Lihua Budde, MD, PhD
Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.
Advertisement
Latest Updated Articles
Discussing the Investigation of Polatuzumab Combination Therapy in DLBCLPublished: October 24th 2023 | Updated:
Dr. Budde Highlights Unique Aspects of Mosunetuzumab Trial in Follicular LymphomaPublished: February 27th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
